ANDA 205322, held by Aurobindo Pharma. Efavirenz.
As of Nov 16, 2026, ANDA 205322 (Efavirenz), held by Aurobindo Pharma, was first approved by FDA on Aug 30, 2018, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 30, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Efavirenz600MG ยท tablet;oral | Efavirenz | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters